Condition

Small Cell Lung Cancer clinical trials and research

• 93Clinical trials
• 179NIH research projects
• 34Countries

Newest Small Cell Lung Cancer clinical trials

All recruiting trials (93)

• Tarlatamab in strong-performance-status small-cell lung cancer

  This trial tests whether tarlatamab can help people with extensive-stage small-cell lung cancer and poor health (ECOG 2) who have already had prior treatment.

  Recruiting at 8 sites Phase 2 AIO-Studien-gGmbH · Berlin and 7 other locations · NCT07803848

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

• Tarlatamab given under the skin vs by IV in extensive-stage small cell lung cancer after platinum therapy

  This trial tests whether subcutaneous tarlatamab works as well as the IV form for people with extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting at 9 sites Phase 3 Amgen · Orlando, Florida and 8 other locations · NCT07778316

• NK Cells Plus Immunotherapy for Extensive-Stage Small Cell Lung Cancer Maintenance

  This study tests whether adding allogeneic NK cell therapy to standard immunotherapy helps people with extensive-stage small cell lung cancer who have disease control after initial chemotherapy and immunotherapy.

  Recruiting Phase 2 Tianjin First Central Hospital · Tianjin, Tianjin Municipality · NCT07759856

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• Teniposide + cisplatin + serplulimab versus etoposide + cisplatin + serplulimab for extensive-stage small-cell lung cancer

  This study tests whether replacing etoposide with teniposide, while keeping cisplatin and serplulimab, works better for adults with extensive-stage small-cell lung cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07583511

• DXC006 with immune therapy or platinum for small cell lung cancer

  This trial tests DXC006 in combination with an immune checkpoint inhibitor or platinum-based chemotherapy to see if it is safe and shows activity in adults with small cell lung cancer.

  Recruiting Phase 1/2 Hangzhou DAC Biotechnology Co., Ltd. · Guangzhou, Guangdong · NCT07559929

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• SMARCA4/2 Inhibitor for POU2F3-Positive Small Cell Lung Cancer

  This trial tests FHD-286, a SMARCA4/2 inhibitor, in people with POU2F3-expressing small cell lung cancer who have already had platinum therapy.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07551635

• DSP-0390 with Atezolizumab in extensive-stage small cell lung cancer

  This pilot phase Ib study tests whether adding DSP-0390 to maintenance atezolizumab after initial chemo-immunotherapy is safe and shows early signs of activity in people with extensive-stage small cell lung cancer who have not progressed.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07545954

• Tarlatamab plus ZL-1310, with or without durvalumab, for small cell lung cancer

  This trial will test whether combining tarlatamab with ZL-1310, with or without the PD-L1 drug durvalumab, is safe and tolerable for adults with small cell lung cancer who have received platinum chemotherapy or are newly diagnosed extensive-stage after one cycle of chemo.

  Recruiting at 27 sites Phase 1 Amgen · Goodyear, Arizona and 26 other locations · NCT07531095

• Autologous B7-H3 CAR T Cells in Advanced Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  This study tests a patient’s own B7-H3 CAR T cells to see if they can help people 18 and older whose small cell lung cancer or EPNEC has come back or hasn’t responded to prior treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07509034

• Using a new PFD3 PET tracer to find and stage small cell lung cancer

  This test will try a new PET tracer called PFD3 in adults with small cell lung cancer to see if it detects tumors and stages disease more accurately than standard FDG PET/CT.

  Recruiting Phase 1/2 Peking University First Hospital · Beijing, Beijing Municipality · NCT07508852

• PF-08634404 with or without chemotherapy for adults with transformed small cell lung cancer

  This will try the experimental drug PF-08634404 by itself and together with chemotherapy in adults whose EGFR-mutated non-small cell lung cancer has turned into transformed small cell lung cancer.

  Recruiting at 55 sites Phase 2 Pfizer · Duarte, California and 60 other locations · NCT07476287

• SYS6043 for adults with advanced or metastatic solid tumors

  This study will try SYS6043 in adults with advanced or metastatic solid tumors who have no standard treatment options to see if it is safe and might shrink tumors.

  Recruiting at 5 sites Phase 1 Conjupro Biotherapeutics, Inc. · Plantation, Florida and 4 other locations · NCT07424547

• Tarlatamab for Small Cell Lung Cancer with Brain Metastases

  This phase II study tests whether tarlatamab can help adults with small cell lung cancer that has spread to the brain, by treating both systemic disease and brain tumors.

  Recruiting at 3 sites Phase 2 Maastricht University Medical Center · Amsterdam and 3 other locations · NCT07402343

• Chidamide plus PD-L1 inhibitor with carboplatin and etoposide for first-line extensive-stage small‑cell lung cancer

  This trial will test whether adding chidamide to a PD-L1 inhibitor together with carboplatin and etoposide helps people with extensive-stage small‑cell lung cancer stay progression‑free longer.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07373964

• ABBV-706 plus standard care for relapsed/refractory small cell lung cancer

  This study tests ABBV-706 to see if it changes disease activity and how safe it is compared with standard care in adults whose small cell lung cancer has returned or progressed.

  Recruiting at 72 sites Phase 3 AbbVie · Birmingham, Alabama and 71 other locations · NCT07365241

• SKB500 combination treatments for extensive-stage small cell lung cancer

  This trial tests SKB500 given with other medicines in adults with extensive-stage small cell lung cancer to see if the combinations are safe and show tumor-fighting activity.

  Recruiting Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07296809

• HLX43 with Serplulimab in advanced lung cancer

  This study tests whether HLX43 given with serplulimab can help adults with advanced NSCLC or SCLC who have had prior chemotherapy and immunotherapy.

  Recruiting at 10 sites Phase 2 Shanghai Henlius Biotech · Hefei, Anhui and 9 other locations · NCT07253142

• ZG006 plus PD‑1/PD‑L1 immunotherapy as first‑line treatment for extensive‑stage small cell lung cancer

  This study will test whether adding ZG006 to PD‑1/PD‑L1 immunotherapy (with or without chemotherapy) is safe and improves outcomes for people with extensive‑stage small cell lung cancer starting first‑line treatment.

  Recruiting Phase 1 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Shanghai, Shanghai Municipality · NCT07231445

• ZL-1310 versus doctor-selected therapy for relapsed small-cell lung cancer (DLLEVATE)

  This will test whether ZL-1310 works better than a doctor-selected therapy for adults whose small-cell lung cancer has returned after prior platinum-based treatment.

  Recruiting at 165 sites Phase 3 Zai Lab (Hong Kong), Ltd. · La Jolla, California and 164 other locations · NCT07218146

• Combination of YL201 and ivonescimab (AK112) for advanced solid tumors

  This trial will test whether combining YL201 and ivonescimab (AK112) helps people with advanced solid tumors, including non‑small cell and small cell lung cancer.

  Recruiting Phase 1/2 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong · NCT07208773

• ZG006 versus investigator-selected chemotherapy for relapsed small-cell lung cancer

  This trial tests whether ZG006 helps people with relapsed small-cell lung cancer live longer than the chemotherapy their doctor would choose.

  Recruiting Phase 3 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Shanghai, Shanghai Municipality · NCT07189455

• DXC014 for adults with advanced solid tumors

  This will test DXC014, an experimental cancer medicine, in adults with advanced solid tumors including small cell lung cancer, melanoma, and prostate cancer.

  Recruiting at 5 sites Phase 1 Hangzhou DAC Biotechnology Co., Ltd. · Beijing, Beijing Municipality and 4 other locations · NCT07177937

• 7T MRI to detect tiny brain metastases in adults with small-cell lung cancer who decline preventive cranial irradiation.

  Try a higher-strength 7T brain MRI to see if it finds tiny brain metastases earlier in adults with small-cell lung cancer who decline preventive cranial radiation.

  Recruiting University of Missouri-Columbia · Columbia, Missouri · NCT07175077

• IDE849 for DLL3-expressing tumors including small-cell lung cancer

  This trial tests IDE849, alone and with durvalumab or IDE161, to see if it is safe and can shrink DLL3-positive tumors in people with small-cell lung cancer or other DLL3-expressing cancers.

  Recruiting at 13 sites Phase 1/2 IDEAYA Biosciences · Denver, Colorado and 12 other locations · NCT07174583

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• ABBV-706 plus atezolizumab versus standard first-line therapy for extensive-stage small cell lung cancer

  This trial will test whether giving ABBV-706 with atezolizumab is safer or more effective than standard first-line chemo plus atezolizumab in adults with previously untreated extensive-stage small cell lung cancer.

  Recruiting at 70 sites Phase 2 AbbVie · New Haven, Connecticut and 69 other locations · NCT07155174

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• GV20-0251 treatment for adults with advanced solid tumors

  This study will test GV20-0251 to see if it helps adults with advanced solid tumors that have stopped responding to approved therapies.

  Recruiting at 3 sites Phase 1/2 GV20 Therapeutics · Beijing, Beijing Municipality and 2 other locations · NCT07070518

• ZG006 plus ZG005 for advanced small cell lung cancer and neuroendocrine carcinoma

  This trial tests whether the combination of ZG006 and ZG005 helps adults with advanced small cell lung cancer or neuroendocrine carcinoma.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Guanzhou, Guangdong · NCT07038096

• Multi-omics blood and tissue testing to predict and monitor treatment response in small cell lung cancer

  This project will test whether combining multiple molecular tests on blood and tumor tissue can predict and track treatment response in people with newly diagnosed small cell lung cancer.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07026669

• AK112 consolidation therapy for limited-stage small cell lung cancer after concurrent chemoradiation

  This trial will test whether the experimental antibody AK112 (ivonescimab) given after successful concurrent chemoradiation can help prevent recurrence in adults with limited-stage small cell lung cancer.

  Recruiting at 52 sites Phase 3 Akeso · Beijing, Beijing Municipality and 52 other locations · NCT07010263

• SYS6040 injection for patients with advanced solid tumors

  This study is testing a new injection called SYS6040 to see if it is safe and effective for people with advanced solid tumors who haven't had success with other treatments.

  Recruiting Phase 1 CSPC Megalith Biopharmaceutical Co.,Ltd. · Changchuan, Jilin · NCT06970795

• Hospital-at-Home program for patients receiving Tarlatamab

  This study is testing if a Hospital-at-Home program can help adults with advanced small cell lung cancer who are getting tarlatamab feel better while being monitored from home instead of staying in the hospital.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06957314

• NMS-03305293 plus temozolomide for adults with relapsed small cell lung cancer.

  This will test whether the experimental drug NMS-03305293 combined with temozolomide helps adults with relapsed small cell lung cancer who progressed after platinum-based therapy.

  Recruiting at 3 sites Phase 1 Nerviano Medical Sciences · Peoria, Illinois and 2 other locations · NCT06931626

• Nano-formulated fenretinide for relapsed or refractory small cell lung cancer

  This trial will test a nanoparticle phospholipid formulation of fenretinide to see if it can be given safely and help people whose small cell lung cancer has returned or not responded to prior treatments.

  Recruiting at 2 sites Phase 1 SciTech Development, Inc. · Los Angeles, California and 1 other locations · NCT06922539

• Evaluating DC05F01 for patients with recurrent ovarian cancer and advanced solid tumors

  This study is testing a new oral treatment called DC05F01 to see if it can help people with recurrent ovarian cancer and other advanced solid tumors feel better.

  Recruiting at 2 sites Phase 1/2 Heronova Pharmaceuticals · Bengbu, Anhui and 1 other locations · NCT06873555

• Using immunonutrition to reduce esophagitis in lung cancer patients undergoing radiotherapy

  This study is testing if a special nutritional drink can help lung cancer patients undergoing radiation therapy experience less throat irritation.

  Recruiting at 6 sites Phase 3 Hunan Cancer Hospital · Changsha, Hunan and 5 other locations · NCT06840704

• Testing a new drug for advanced solid tumors that express c-Kit

  This study is testing a new drug for people with advanced solid tumors that have a specific marker called c-Kit to see if it is safe and how well it works.

  Recruiting at 4 sites Phase 1 Novelty Nobility, Inc. · Ann Arbor, Michigan and 4 other locations · NCT06805825

• Evaluating new treatments for relapsed small cell lung cancer

  This study is testing two new drugs to see if they can help people with advanced small cell lung cancer that hasn't responded to other treatments.

  Recruiting at 44 sites Phase 1/2 Merck Sharp & Dohme LLC · Aurora, Colorado and 47 other locations · NCT06780137

• Combining radiotherapy with immunotherapy for extensive small cell lung cancer

  This study is testing if combining radiation therapy with a type of immunotherapy can help people with extensive small cell lung cancer live longer after their initial treatment.

  Recruiting Phase 2 Regina Elena Cancer Institute · Rome, Rome · NCT06771518

• Combining Ivonescimab and Cadonilimab with chemotherapy for extensive stage small cell lung cancer

  This study is testing if combining two new drugs, Ivonescimab and Cadonilimab, with chemotherapy can help people with extensive stage small cell lung cancer feel better compared to standard treatments.

  Recruiting Phase 2 Sichuan University · Chengdu, Sichuan · NCT06769971

• Understanding resistance to chemo-immunotherapy in aggressive lung cancers

  This study is trying to understand why some adults with aggressive lung cancers don’t respond to chemo-immunotherapy, so they can find better treatment options for these patients.

  Recruiting Oncology Center of Biochemical Education And Research · New York, New York and 1 other locations · NCT06717243

• Evaluating IBI3009 for advanced small cell lung cancer

  This study is testing a new treatment called IBI3009 to see if it's safe and how much can be given to people with advanced small cell lung cancer that can't be removed by surgery.

  Recruiting at 4 sites Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Westmead, New South Wales and 9 other locations · NCT06613009

• Testing ZG006 for small cell lung cancer patients who have not responded to standard treatments

  This study is testing a new treatment called ZG006 for people with small cell lung cancer who haven't had success with standard treatments to see if it can help them.

  Recruiting at 3 sites Phase 1 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Orange, California and 5 other locations · NCT06592638

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Combining hypofractionated radiotherapy with immunotherapy for limited-stage small-cell lung cancer

  This study is testing if a shorter radiation treatment combined with a new immunotherapy can help people with limited-stage small-cell lung cancer live longer without their cancer getting worse.

  Recruiting Phase 1/2 Anhui Provincial Hospital · Hefei, Anhui · NCT06527898

• Combining chemoimmunotherapy with radiation for extensive stage small-cell lung cancer

  This study is testing if combining a new type of cancer treatment with radiation can help people with advanced small-cell lung cancer live longer and feel better.

  Recruiting at 3 sites Qingdao Central Hospital · Qingdao, Shandong and 2 other locations · NCT06514118

• Evaluating BL-M14D1 for advanced small cell lung cancer and other solid tumors

  This study is testing a new treatment called BL-M14D1 to see if it can help people with advanced small cell lung cancer and other solid tumors who have run out of other treatment options.

  Recruiting Phase 1 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06505824

• Using Adebrelimab and Apatinib for treating advanced small cell lung cancer

  This study is testing if a combination of Adebrelimab and Apatinib can help people with advanced small cell lung cancer live longer and feel better after their initial treatment.

  Recruiting China Medical University, China · Shenyang, Liaoning and 1 other locations · NCT06480864

• Therapeutic effects of irinotecan liposomes for small cell lung cancer

  This study is testing if a new treatment using irinotecan liposomes can help people with small cell lung cancer who haven't responded to their first treatment feel better and live longer.

  Recruiting Phase 4 Tang-Du Hospital · Xi'an, Shannxi · NCT06467786

• Comparing two radiation therapies for brain metastases in small-cell lung cancer

  This study is testing whether two types of targeted radiation therapy can be better options than standard whole brain radiation for people with small-cell lung cancer that has spread to the brain.

  Recruiting Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06457906

• Using fingolimod to treat advanced lung cancers

  This study is testing if fingolimod can safely help people with advanced lung cancer who haven't improved with other treatments.

  Recruiting Phase 2 Medical University of South Carolina · Charleston, South Carolina · NCT06424067

• Combining Serplulimab with Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer

  This study is testing if adding Serplulimab to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer live longer and feel better.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06295926

• Testing ZG006 for advanced small cell lung cancer and neuroendocrine carcinoma

  This study is testing a new treatment called ZG006 to see if it is safe and effective for people with advanced small cell lung cancer and neuroendocrine carcinoma.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Shanghai, Shanghai Municipality · NCT06283719

• Observational study on characteristics and outcomes of patients with surgically removed lung cancers

  This study looks at patients in China who have had lung cancer surgery to see how their treatment and outcomes vary and what factors might affect their survival.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06255197

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

• Comparing Ifinatamab Deruxtecan to Physician's Choice for Relapsed Small Cell Lung Cancer

  This study is testing if a new drug called Ifinatamab deruxtecan can help people with relapsed small cell lung cancer more than the treatments their doctors usually choose.

  Recruiting at 189 sites Phase 3 Daiichi Sankyo · Springdale, Arkansas and 228 other locations · NCT06203210

• Analyzing long-term survivors of aggressive solid tumors

  This study looks at patients who have survived much longer than expected from aggressive solid tumors to see what makes them different and if it can help develop new treatments.

  Recruiting Cure 51 · Villejuif · NCT06160596

• Combining systemic therapy with local ablative treatments for certain lung cancers

  This study is testing if adding local treatments to ongoing therapy can help people with certain lung cancers live longer without their disease getting worse.

  Recruiting University of California, Davis · Sacramento, California · NCT06103682

• Evaluating alisertib for extensive stage small cell lung cancer

  This study is testing whether a drug called alisertib can help people with advanced small cell lung cancer who have already tried other treatments.

  Recruiting at 26 sites Phase 2 Puma Biotechnology, Inc. · Daphne, Alabama and 29 other locations · NCT06095505

• Testing NEO212 for treating certain brain tumors and metastases

  This study is testing a new treatment called NEO212 for people with certain types of brain tumors to see if it is safe and effective when combined with standard treatments.

  Recruiting at 8 sites Phase 1/2 Neonc Technologies, Inc. · Beverly Hills, California and 7 other locations · NCT06047379

• Evaluating BL-B01D1 for patients with advanced lung and solid tumors

  This study is testing a new treatment called BL-B01D1 to see if it is safe and effective for people with advanced lung cancer and other solid tumors.

  Recruiting at 37 sites Phase 1 SystImmune Inc. · Beverly Hills, California and 36 other locations · NCT05983432

• Treatment of small cell lung cancer and neuroendocrine carcinoma with ZG006

  This study is testing a new drug called ZG006 to see if it can help adults with small cell lung cancer or neuroendocrine carcinoma who have run out of other treatment options.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Zhengzhou, Henan · NCT05978284

• Analysis and treatment options for small cell lung cancer

  This study looks at small cell lung cancer to see how its unique features can help doctors find better treatments and predict how well patients will respond to new therapies.

  Recruiting Shanghai Chest Hospital · Shanghai · NCT05945745

• Testing new treatments for extensive stage small cell lung cancer

  This study is testing three different treatment options for people with extensive-stage small cell lung cancer who haven't had success with other therapies to see which one works best.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Changchun, Jilin · NCT05924841

• Combination treatment for extensive stage small cell lung cancer

  This study is testing a new combination treatment for people with extensive stage small cell lung cancer to see if it helps them live longer and feel better.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Indianapolis, Indiana and 3 other locations · NCT05903092

• Rapid autopsy program for small cell lung cancer patients

  This study is trying to set up a quick way to collect and analyze tumor samples from small cell lung cancer patients after they pass away to help find important markers for the disease.

  Recruiting at 3 sites Indiana University · Indianapolis, Indiana and 2 other locations · NCT05889546

• Dose-reduced chemotherapy for lung cancer patients with health issues

  This study is testing if a lower dose of chemotherapy can help lung cancer patients with other health issues feel better and manage their treatment safely.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT05800587

• Innovative immune assays for small cell lung cancer

  This study is testing new ways to understand how the immune system responds in people with small cell lung cancer to see if it can help predict their treatment outcomes.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT05797493

• Tracking lung cancer evolution through therapy

  This study is trying to see how lung cancer changes during treatment in people with different types of the disease by collecting health information and samples over two years.

  Recruiting University College, London · London · NCT05628376

• Combining Trilaciclib with Lurbinectedin for Small-cell Lung Cancer

  This study is testing if adding Trilaciclib can help reduce side effects from Lurbinectedin in patients with advanced small-cell lung cancer who have already tried other treatments.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Lebanon, New Hampshire and 1 other locations · NCT05578326

• Radiotherapy for advanced small-cell lung cancer after chemotherapy

  This study is testing if adding radiation therapy to ongoing treatment can help people with advanced small-cell lung cancer who haven't gotten worse after chemotherapy.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT05552846

• Using Onvansertib to treat relapsed small cell lung cancer

  This study is testing a new drug called onvansertib to see if it can help people with relapsed small cell lung cancer who haven't had success with chemotherapy.

  Recruiting Phase 2 University of Maryland, Baltimore · Baltimore, Maryland and 1 other locations · NCT05450965

• Stereotactic radiosurgery for lung cancer that has spread to the brain

  This study is testing if a targeted radiation treatment can help people with small cell lung cancer that has spread to their brain feel better and improve their outcomes.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05419076

• Evaluating AL8326 for advanced small cell lung cancer treatment

  This study is testing a new drug called AL8326 to see if it can help people with advanced small cell lung cancer who need a second treatment option.

  Recruiting at 5 sites Phase 2 Advenchen Laboratories, LLC · Birmingham, Alabama and 6 other locations · NCT05363280

• Observational study on small cell lung cancer patients receiving standard care

  This study looks at small cell lung cancer patients receiving their usual treatment to see how their tumor and blood samples can help us understand the disease better and improve future treatments.

  Recruiting at 7 sites Tempus AI · Los Alamitos, California and 10 other locations · NCT05257551

• Combining durvalumab with radiation for extensive-stage small cell lung cancer

  This study is testing if adding a new drug called durvalumab to radiation and chemotherapy can help people with extensive-stage small cell lung cancer live longer without their cancer getting worse.

  Recruiting Phase 2 University of Chicago · Chicago, Illinois and 1 other locations · NCT05068232

• Adaptive radiotherapy for small cell lung cancer treatment

  This study is testing a new type of personalized radiation therapy for people with small cell lung cancer to see if it can better control the cancer and reduce side effects compared to standard treatments.

  Recruiting Phase 2 AHS Cancer Control Alberta · Edmonton, Alberta · NCT04952480

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Combination of PD-L1 antibody and chemotherapy for small-cell lung cancer

  This study is testing a new combination of a PD-L1 antibody and chemotherapy to see if it helps people with limited-stage small-cell lung cancer feel better as their first treatment.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT04539977

• Collection of tumor samples from cancer patients for diagnostic test development

  This study is collecting tumor samples from cancer patients who are getting certain treatments to help create better tests for managing cancer in the future.

  Recruiting Cofactor Genomics, Inc. · San Francisco, California · NCT04510129

• Using proton therapy to treat small cell lung cancer

  This study tests whether a new type of radiation therapy called proton therapy is safer and more effective for people with small cell lung cancer compared to standard treatments.

  Recruiting Emory University · Atlanta, Georgia · NCT04342429

• Imaging small cell lung cancer with a new tracer

  This study is testing a new imaging agent to see if it can help doctors better see and identify small cell lung cancer and some related tumors in patients.

  Recruiting Phase 1/2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT04199741

• Combining talazoparib with low dose radiotherapy for extensive-stage small cell lung cancer

  This study is testing if combining a new drug called talazoparib with low dose radiation can help people with extensive-stage small cell lung cancer who have stable disease after chemotherapy.

  Recruiting Phase 1 University Health Network, Toronto · Toronto, Ontario · NCT04170946

• Combining acetazolamide with chemotherapy and radiotherapy for small cell lung cancer

  This study is testing if adding acetazolamide to chemotherapy and radiotherapy can help people with small cell lung cancer get better results from their treatment.

  Recruiting Phase 1 Centre Antoine Lacassagne · Nice and 1 other locations · NCT03467360

• Infusing iNKT and PD-1+ CD8+ T cells for advanced solid tumors

  This study will try giving people with advanced lung, pancreatic, liver, stomach, or colon cancers infusions of iNKT cells and PD-1+ CD8+ T cells to see if tumors shrink and survival improves.

  Recruiting Phase 1/2 Shanghai Public Health Clinical Center · Shanghai, Shanghai Municipality · NCT03093688

• Platform for assessing molecular testing and treatment outcomes in lung cancer patients

  This study is trying to gather and analyze information about treatments and outcomes for people with lung cancer to improve care and understand their quality of life better.

  Recruiting AIO-Studien-gGmbH · Oldenburg · NCT02622581

• Collecting tissue samples from patients with various types of lung cancer

  This study is collecting tissue samples from adults with different types of lung cancer to learn more about the disease and improve future treatments.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT02146170

NIH-funded research (newest 40 of 179)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• ABL kinase signaling and DNA collisions in small cell lung cancer

  A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.

  NIH research Duke University · Durham, United States · NIH-11460190

• XRN1 as a potential therapy target in lung cancer

  A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11457022

• Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer

  This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.

  NIH research Rlr VA Medical Center · Indianapolis, United States · NIH-11456786

• Targeting STRAP to curb NSCLC spread with nanoparticle therapy

  Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11447387

• Modeling tumor differences to guide new treatments for resistant small cell lung cancer

  A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11445820

• TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy

  A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.

  NIH research West Virginia University · Morgantown, United States · NIH-11413683

• Telomere-targeting Therapy plus cemiplimab for advanced NSCLC

  A new drug called THIO, used with an immune therapy, is being tested for people with advanced non-small cell lung cancer whose previous treatments stopped working.

  NIH research Maia Biotechnology, INC. · Chicago, United States · NIH-11411298

• Novel ribosome-building drugs for small cell lung cancer (RiBi inhibitors)

  A new class of medicines aims to stop ribosome production in small cell lung cancer cells to slow or stop tumor growth.

  NIH research Palade Therapeutics INC. · Austin, United States · NIH-11408329

• Targeting GARP-TGFβ to Improve Immunotherapy in NSCLC

  A new antibody approach aims to block a key TGFβ-related pathway in the tumor environment to help people with non-small cell lung cancer respond better to therapy.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11400422

• DLL3-targeted IL18-secreting CAR T cells for Small Cell Lung Cancer

  A new, patient-facing immunotherapy approach uses specially engineered CAR T cells to target DLL3 in small cell lung cancer with the goal of improving durability of response and survival.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11399164

• Targeting LSD1 to boost immune therapy for small cell lung cancer

  A funded project aims to help people with small cell lung cancer by using a drug that inhibits LSD1 to make immune therapy work better.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11397788

• CAR-T therapy targets for small cell lung cancer (SCLC) using autoantigen-derived targets

  A patient-focused look at a program aiming to use specially engineered immune cells to target SCLC by recognizing tumor-specific surface markers.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11393896

• Brain metastasis targeting and therapy in small cell lung cancer

  A new plan to study why small cell lung cancer spreads to the brain and how to treat those brain metastases with safer, more effective options.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11391984

• Targeting replication stress to boost immune therapy in small cell lung cancer

  A doctor-scientist team at Ohio State University is testing a new approach to make immune checkpoint therapies work better for people with small cell lung cancer.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11391332

• Targeting replication stress to improve treatment for small cell lung cancer

  A large NIH grant is supporting research to understand why small cell lung cancer stops responding to chemotherapy and to find new ways to overcome resistance.

  NIH research New York University School of Medicine · New York, United States · NIH-11390982

• Targeting DHX9 to boost viral-like immune response in Small Cell Lung Cancer

  A scientist team is testing whether blocking a protein called DHX9 can make aggressive small cell lung cancer more visible to the immune system and more responsive to immunotherapy.

  NIH research Research Inst of Fox Chase Can Ctr · Philadelphia, United States · NIH-11386506

• How air pollution and neighborhood stress affect lung tumors in African American patients

  This project looks at whether long-term air pollution and neighborhood disadvantage change tumor DNA and short-term recurrence risk in early-stage lung cancer among African American patients.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11379068

• Novel therapeutic approaches for small cell lung cancer (SCLC) using CRISPR-based methods

  Aimed at developing new treatments for small cell lung cancer by using CRISPR-based approaches to target diverse tumor cells and improve therapies.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11378420

• Integrated MRI and blood markers to predict radiation failures in brain metastases from NSCLC

  Aims to build a person-friendly model using MRI scans and blood biomarkers to predict how brain metastases from non-small cell lung cancer will respond to radiation therapy.

  NIH research Wake Forest University Health Sciences · Winston-Salem, United States · NIH-11374199

• Advanced machine learning to improve blood-based cancer detection in melanoma and lung cancer

  A physician-scientist is using cutting-edge AI to make blood tests for melanoma and non-small cell lung cancer much more sensitive, so doctors can monitor cancer without relying on scans.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11370107

• Autoantibodies as early signals and imaging guides for small cell lung cancer

  A blood-based test using autoantibodies may help detect small cell lung cancer early and guide non-invasive imaging to confirm and map tumors.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11369095

• PBAF chromatin remodeling and small cell lung cancer

  This NIH grant explores how a chromatin-remodeling complex called PBAF influences the development and progression of small cell lung cancer and what this means for future therapies.

  NIH research Yale University · New Haven, United States · NIH-11368422

• Inter-metastatic divergency in small cell lung cancer and future immunotherapies

  A Duke-led study aims to understand why small cell lung cancer (SCLC) cells differ across metastases and how this affects immune-based treatments.

  NIH research Duke University · Durham, United States · NIH-11364956

• Targeting the CARM1-NFIB pathway to treat small cell lung cancer

  This project studies how a specific protein interaction drives small cell lung cancer and tests new ways to block it to help patients.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11364113

• Modulating cysteine metabolism to kill small cell lung cancer cells

  A Stanford-led research project aims to find new ways to trigger death in aggressive small cell lung cancer by targeting how these cancer cells use cysteine.

  NIH research Stanford University · Stanford, United States · NIH-11357646

• Understanding and Overcoming Chemoresistance in Small Cell Lung Cancer

  Aims to identify what drives resistance to chemotherapy in small cell lung cancer to help develop better treatment options for patients.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11357546

• Targeting Jumonji KDM4A to Fight Small Cell Lung Cancer

  A tiny 2-year research grant tests whether blocking a specific epigenetic enzyme can slow or stop small cell lung cancer in mouse models and guide future therapies.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11354463

• Ketogenic metabolic therapy to boost hormone/immunity therapy in lung cancer patients

  A new approach combines a ketogenic metabolic therapy with immune checkpoint therapy to help people with non-small cell lung cancer respond better.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11350471

• Proteogenomic clues to NSCLC recurrence in early-stage lung cancer

  A national study will look at the tumor’s genetic and protein signals to find clues about which early-stage non-small cell lung cancer may come back after surgery.

  NIH research Washington University · Saint Louis, United States · NIH-11345500

• VEL-03: a new treatment approach for lung cancer and other solid tumors

  A new drug candidate called VEL-03 aims to slow or stop the growth of non-small cell lung cancer and other solid tumors by targeting cancer cell metabolism.

  NIH research Velorum Therapeutics INC. · Plano, United States · NIH-11345350

• Targeted therapy combo for KRAS/KEAP1-mutant lung cancer

  A new NIH-funded project tests a two-drug approach to treat a hard-to-kill form of lung cancer driven by KRAS and KEAP1 mutations.

  NIH research Rush University Medical Center · Chicago, United States · NIH-11336415

• Propionate metabolism’s role in lung cancer progression and drug resistance

  A physician-scientist is studying how a little-known metabolic pathway, propionate metabolism, may drive metastasis and drug resistance in non-small cell lung cancer and how targeting it could help patients.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11333755

• Understanding RAMS11 and its role in non-small cell lung cancer

  This grant studies how a brainy RNA molecule called RAMS11 may drive aggressive non-small cell lung cancer and could lead to better biomarkers and targeted therapies for patients.

  NIH research Washington University · Saint Louis, United States · NIH-11333332

• Antigen targets of tumor-fighting T cells in lung cancer

  A physician-scientist training program focuses on how T cells recognize lung cancer antigens to guide future therapies.

  NIH research Yale University · New Haven, United States · NIH-11332630

• Integrated blood and radiomics to guide immunotherapy in metastatic NSCLC

  A research project aims to use blood tests and advanced imaging patterns to personalize first-line immunotherapy choices for people with metastatic non-small cell lung cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11332497

• MasSpec Pen helps surgeons quickly check lung cancer during surgery

  A new device called MasSpec Pen may help surgeons rapidly and safely determine if a lung nodule is cancerous and whether margins are clean during lung cancer operations.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11330406

• Blood and airway microbe and gene tests to find and predict early non-small cell lung cancer

  This project looks for microbial and host gene signals in blood and airway samples to help spot early non-small cell lung cancer and predict who might have the cancer come back.

  NIH research New York University School of Medicine · New York, United States · NIH-11325339

• Coordinating center supporting small cell lung cancer research collaboration

  A national coordinating center helps researchers, clinicians, and patient advocates share data, models, and resources to speed advances against small cell lung cancer.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11321553

• Understanding how RBM10 loss affects immune escape in KRAS-mutant lung cancer

  This research aims to understand why some KRAS-mutant lung cancers resist immune therapy and how RBM10 loss changes tumor immunity, with the goal of finding new ways to help patients respond to treatment.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11321289

• Detecting and removing drug-tolerant cells in small cell lung cancer

  This project aims to find and destroy the rare drug-tolerant cells that allow small cell lung cancer to come back after treatment, to help people with SCLC stay cancer-free longer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11320838

Related topics

Quick answers

How many Small Cell Lung Cancer clinical trials are recruiting right now?

93, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 34 countries. The most sites are in United States (46 trials), China (43 trials), Spain (11 trials), Australia (10 trials), France (10 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 25, Phase 1: 20, Phase 1/2: 17, Phase 3: 9. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →